Lunghi Carlotta, Moisan Jocelyne, Grégoire Jean-Pierre, Guénette Line
From the Faculty of Pharmacy (CL, JM, J-PG, LG); Chair on Adherence to Treatments (CL, JM, J-PG, LG), Laval University; and Population Health and Optimal Health Practices Research Unit, CHU de Québec Research Centre (CL, JM, J-PG, LG), Quebec, QC, Canada.
Medicine (Baltimore). 2016 May;95(21):e3514. doi: 10.1097/MD.0000000000003514.
It has been reported that the risk of depression is higher among people with type 2 diabetes compared with a nondiabetic population. Among diabetic patients, depression has been associated with worse self-care behaviors, poor glycemic control, and an increased risk of diabetes complications. Identifying factors associated with the occurrence of depression may help physicians identify earlier diabetic patients at a high risk of developing depression, improve prevention, and accelerate proper treatment. To our knowledge, very few population-based studies have reported on the incidence of clinically diagnosed depression as a consequence of type 2 diabetes over a long follow-up period. The objective of this study was to estimate the incidence of clinically diagnosed depression among type 2 diabetic patients newly treated with oral antidiabetic drugs (ADs) and to identify factors associated with the occurrence of depression.Administrative claims data from the public health insurance plan were used to identify a cohort of new oral AD users aged ≥18 years between 2000 and 2006. Patients were followed from oral AD treatment initiation until the diagnosis of depression, ineligibility for the public drug plan, death, or the end of the study, whichever came first. Incidence rates were determined using person-time analysis. Factors associated with depression were identified using multivariable Cox regression analysis.We identified 114,366 new oral AD users, of which 4808 had a diagnosis of depression. The overall incidence rate of depression was 9.47/1000 person-years (PYs) (10.72/1000 PYs for women and 8.27/1000 PYs for men). The incidence of depression was higher during the year after oral AD treatment initiation. Independent factors associated with depression included having had mental disorders other than depression, hospitalization, a higher number of different drugs taken and of physicians visited during the year before oral AD initiation. Moreover, we observed a statistically significant age-by-socioeconomic status interaction.The incidence of diagnosed depression is higher during the first year after oral AD treatment initiation. Clinicians could pay particular attention to women, patients starting an AD at a young age, those with a low socioeconomic status, and especially those with a history of anxiety or dementia.
据报道,与非糖尿病人群相比,2型糖尿病患者患抑郁症的风险更高。在糖尿病患者中,抑郁症与较差的自我护理行为、血糖控制不佳以及糖尿病并发症风险增加有关。识别与抑郁症发生相关的因素可能有助于医生更早地识别出有患抑郁症高风险的糖尿病患者,改善预防措施,并加速适当治疗。据我们所知,很少有基于人群的研究报告2型糖尿病在长期随访期间导致临床诊断抑郁症的发生率。本研究的目的是估计新接受口服抗糖尿病药物(ADs)治疗的2型糖尿病患者中临床诊断抑郁症的发生率,并识别与抑郁症发生相关的因素。利用公共医疗保险计划的行政索赔数据,确定了2000年至2006年间年龄≥18岁的新口服AD使用者队列。从口服AD治疗开始对患者进行随访,直至诊断出抑郁症、不符合公共药物计划资格、死亡或研究结束,以先发生者为准。发病率采用人时分析确定。使用多变量Cox回归分析识别与抑郁症相关的因素。我们确定了114366名新的口服AD使用者,其中4808人被诊断为抑郁症。抑郁症的总体发病率为9.47/1000人年(女性为10.72/1000人年,男性为8.27/1000人年)。口服AD治疗开始后的第一年抑郁症发病率较高。与抑郁症相关的独立因素包括除抑郁症外患有精神障碍、住院、口服AD开始前一年服用的不同药物数量较多以及就诊医生数量较多。此外,我们观察到年龄与社会经济地位之间存在统计学显著的相互作用。口服AD治疗开始后的第一年诊断出抑郁症的发病率较高。临床医生应特别关注女性、年轻时开始使用AD的患者、社会经济地位较低的患者,尤其是有焦虑或痴呆病史的患者。